Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Hepatology. 2018 Mar 26;67(5):1931–1942. doi: 10.1002/hep.29694

Table 3.

Clinical characteristics of patients with ALF who received or did not receive red blood cell transfusion during days 1–7.

Clinical Feature N No RBC Transfusions
N = 1119 (Mean N, %)
RBC Transfusions
N = 651 (Mean N, %)
P
Demographics
Age (Years) 1770 42±15 41±14 0.15
Gender (% Female) 1770 744(66.5) 477(73.3) 0.003
Race (Caucasian) 1770 842(75.2) 467(71.7) 0.117
APAP Etiology of ALF 1770 523(46.7) 275(42.2) 0.075
Clinical Features on Admission
SIRS (% ≥ 2 ) 1364 580(72.0) 444(79.4) 0.002
Ammonia (μM) 1032 98.0±90.0 101.0±97.0 0.826
Encephalopathy Grade (% 3/4) 1721 451(41.9) 397(61.6) < 0.001
Creatinine (mg/dl) 1766 1.3±1.9 2.1±2.3 <0.001
INR 1770 2.9±2.2 2.8±2.2 0.129
Total bilirubin (mg/dl) 1752 7.0±15.6 8.0±17.0 <0.001
Albumin (g/dl) 1616 2.7±0.7 2.7±0.8 0.17
Lactate (mg/dl) 971 3.9±4.7 5.9±7.7 <0.001
Bicarbonate (mg/dl) 1481 22.0±8.0 20.0±8.8 <0.001
Phosphate (mg/dl) 1539 3.0±2.2 3.4±2.7 <0.001
Platelet count (×109/L) 1770 133.0±104.0 108.0±102.5 <0.001
WBC (×109/L) 1770 9.6±7.4 10.9±9.9 <0.001
Hemoglobin (g/dl) 1764 11.5±2.9 9.9±2.9 <0.001
Clinical Features after Admission, Days 1–7
INR peak 1770 3.3±2.7 3.3±2.8 0.586
Platelet count nadir (×109/L) 1770 94.0±81.0 50.0±48.0 <0.001
Hemoglobin nadir (g/dl) 1770 9.8±2.5 8.2±1.6 <0.001
Encephalopathy Grade ¾ 1734 613(56.3) 529(82.0) < 0.001
Infection 1770 125(11.2) 46(7.1) 0.006
Bleeding Complication 1770 67(6.0) 120(18.4) < 0.001
Interventions after Admission, Days 1–7
ICP Monitor Placement 1634 99(9.4) 138(23.7) < 0.001
Renal Replacement Therapy 1770 271(24.2) 370(56.8) < 0.001
Vasopressors 1770 300(26.8) 352(54.1) < 0.001
N-acetylcysteine 1770 722(64.5) 366(56.2) < 0.001
Gastric Acid Suppression 1770 892(79.7) 537(82.5) 0.172
Plasma Transfusion 1770 210(18.8) 85(13.1) 0.002
Platelet Transfusion 1770 451(40.3) 543(83.4) < 0.001